The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Complementary business models are the reason for the acquisition
This deal makes Meddo, one of the largest health-tech players in India
Drug formulations and biologics make impressive gains
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Subscribe To Our Newsletter & Stay Updated
